PharmAI GmbH and Nuclide Therapeutics Ltd (NTx) have entered into a strategic collaboration to co-develop novel small-molecule radiotheranostics. The joint discovery program will combine PharmAI’s DiscoveryEngine platform with NTx’s expertise in theranostic design and clinical development.
